News & Updates
Filter by Specialty:
BRCA-negative ovarian cancer gets PFS gains with pembrolizumab plus olaparib
First-line treatment with chemotherapy plus pembrolizumab followed by maintenance with pembrolizumab plus olaparib, with or without bevacizumab, appears to prolong progression-free survival (PFS) in advanced epithelial ovarian cancer without BRCA 1/2 mutations, according to data from the phase III ENGOT-ov43/GOG-3036/KEYLYNK-001 trial.
BRCA-negative ovarian cancer gets PFS gains with pembrolizumab plus olaparib
08 May 2025
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
07 May 2025
Cancer therapy takes a toll on women’s sexual health
In women being treated for cervical cancer, chemotherapy and radiotherapy appear to have a substantial and lasting negative effect on sexual health, including satisfaction and desire, as shown in a descriptive cross-sectional study conducted in Brazil.
Cancer therapy takes a toll on women’s sexual health
06 May 2025
Letrozole-abemaciclib plus metformin shows promise in endometrial cancer treatment
Adding metformin to letrozole and abemaciclib does not cause serious safety concerns and may even encourage favourable responses among patients with oestrogen receptor (ER)-positive recurrent endometrial cancer (EC), according to a phase II study presented at SGO 2025.
